Advertisement

Statistische Bewertung von Therapieergebnissen

  • L. Edler

Zusammenfassung

Die methodisch abgesicherte und verallgemeinerungsfähige medizinische Erkenntnis über die Therapie von Erkrankungen wird mittels klinischer Studien an Patientenpopulationen erworben. Dieses Kapitel führt in die Planung, Durchführung und Auswertung dieser Studien ein und präsentiert statistische Methodik zur Beantwortung der medizinischen Fragestellung. Entscheidend für eine statistische Bewertung von Therapieergebnissen ist der Studientyp und die Relevanz der klinischen Zielgröße. Der individuellen Variabilität der therapeutischen Antwort der Patienten wird durch die Berechnung von Standardfehlern und Vertrauensbereichen statistischer Schätzungen und durch die Fehlerwahrscheinlichkeiten statistischer Entscheidungen in Hypothesentests Rechnung getragen. Die Wahl der Auswerteverfahren richtet sich nach dem Datentyp der klinischen Antwort und umfasst Mittelwerte, Raten und Zeiten bis zum Eintritt einer klinischen Antwort. Die richtige Benutzung von Basisinformation bei Behandlungsbeginn, Verhalten bei Multiplizität und Methoden zur Qualitätssicherung und der Berichterstattung sind wichtige Teilaspekte einer statistischen Bewertung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altman DG, Dore CJ (1990) Randomisation and baseline comparisons in clinical trials. Lancet 335: 149–153PubMedCrossRefGoogle Scholar
  2. Bauer P (1991) Multiple testing in clinical trials. Stat Med 10: 871–890PubMedCrossRefGoogle Scholar
  3. Begg CB, Zelen M, Carbone PP et al. (1983) Cooperative groups and community hospitals: Measurement of impact in the community hospitals. Cancer 52: 1760–1767PubMedCrossRefGoogle Scholar
  4. Begg C, Cho M, Eastwood S et al. (1996) Improving the quality of reporting of randomized controlled clinical trials: The CONSORT Statement. DAMA 276: 637–639Google Scholar
  5. Benson AB3rd, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K (1991) Oncologist’s reluctance to accrue patients onto clinical trials: An Illinois Cancer Center Study. J Clin Oncol 9: 2067–2075PubMedGoogle Scholar
  6. Buyse ME (1998) Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308Google Scholar
  7. Buyse ME, Staquet MJ, Silvester RJ (1984) Cancer clinical trials: Methods and practice. Univ. Press, OxfordGoogle Scholar
  8. Buyse ME, Zeleniuch-Jacquotte A, Chalmers T (1988) Adjuvant therapy of colorectal cancer: Why we still don’t know. J Am Med Assoc 259: 3571–3578CrossRefGoogle Scholar
  9. Byar DP, Simon RM, Friedewald WT et al. (1976) Randomized clinical trials: Perspectives on some recent ideas. N Engl J Med 295: 74–80PubMedCrossRefGoogle Scholar
  10. Collet D (1994) Modelling survival data in medical research. Chapman & Hall, LondonGoogle Scholar
  11. Cox DR (1972) Regression models and life tables (with discussion). J Roy Stat Soc B 74: 187–220Google Scholar
  12. Diem K (1980) Wissenschaftliche Tabellen Geigy, 8th edn. Ciba-Geiy, BaselGoogle Scholar
  13. Edler L (1993) Phase II Studien in der Onkologie: Wie viele Patienten sind erforderlich? Tumordiagn Therap 14: 1–9Google Scholar
  14. Edler L (1996) Statistik und Biometrie: Trends, Kriterien und Bewertungen. In: Fritze D (Hrsg) Palliative Krebsbehandlung, Zuckschwerdt, Darmstadt, S 3–17Google Scholar
  15. Edler L, Flechtner H (1987) Remission in Phase-II und Phase-III Studien: Kriterien und Voraussetzungen. Onkologie 10: 330–339PubMedCrossRefGoogle Scholar
  16. Fisher B, Wolmark N, Rockette H et al. (1988) Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer. Results from NSABP Protocol R-01. J Natl Cancer Inst 80: 21–29PubMedCrossRefGoogle Scholar
  17. Fleiss JL (1973) Statistical methods for rates and proportions. Wiley, New YorkGoogle Scholar
  18. Fleming TR, Harrington DP, O’Brien PC (1984) Designs for group sequential tests. Control Clin Trials 5: 348–361PubMedCrossRefGoogle Scholar
  19. George SL (1988) Identification and assessment of prognostic factors. Semin Oncol 15: 462–471PubMedGoogle Scholar
  20. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahl-man L, Sjöden PO (1995) Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann On-col 6: 267–274Google Scholar
  21. Goligher JG, Pulvertaft CN, Watkinson G (1964) Controlled trial of vagotomy and gastro-enterostomy, vagotomy and antrectomy, and subtotal gastrectomy in elective treatment of duodenal cancer: Interim report. Br Med J 1: 455–460PubMedCrossRefGoogle Scholar
  22. Green SJ, Fleming TR (1988) Guidelines for the reporting of clinical trials. Semin Oncol 15: 455–461PubMedGoogle Scholar
  23. Hanauske AR, Edler L (1996) New clinical trial designs for phase I studies in hematology and oncology: Principles and practice of the continual reassessment model. Onkologie 19: 404–409CrossRefGoogle Scholar
  24. Haye R de la, Herbold M (2000) Anwendungsbeobachtungen: Leitfaden für die praktische Durchführung. Editio Cantor, AulendorfGoogle Scholar
  25. Hunter CP, Frelick RW, Feldman AR et al. (1987) Selection factors in clinical trials: Results for the Community Clinical Oncology Program Physician’s Patient Log. Cancer Treat Rep 71: 559–565PubMedGoogle Scholar
  26. Kalbfleisch JD, Prentice, RL (1980) Analysis of failure time data. Wiley, New YorkGoogle Scholar
  27. Koch GG, Gansky SA (1996) Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 30: 523–534CrossRefGoogle Scholar
  28. Korn EL, Baumrind S (1998) Clinician preferences and the esti-mation of causal treatment differences. Stat Sci 13: 209–235CrossRefGoogle Scholar
  29. Kreuser ED, Fiebig HH, Scheulen ME et al. (1998) Standard operating procedures and organization of German phase I, II, and III study groups, new drug development group (AWO) of pharmacology in oncology and hematology (APOH) of the Association for Medical Oncology (AIO) of the German Cancer Society. Onkologie 21: Suppl 3Google Scholar
  30. Lefering R, Neugebauer E (1998) Problems of randomized controlled clinical trials (RCT) in surgery. In: Abel U, Koch A (eds) Nonrandomized comparative clinical studies. Symposion Publishing, Düsseldorf, pp 67–75Google Scholar
  31. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherap Rep 50: 163–170Google Scholar
  32. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748PubMedGoogle Scholar
  33. Mehta C, Patel N (1995) StatXact for Windows. User Manual. Cytel Software, Cambridge/MAGoogle Scholar
  34. Meinert CL (1989) The hypertension prevention trial: Design, methods, and baseline results. Control Clin Trials 10: 117CrossRefGoogle Scholar
  35. O’Brien PC (1984) Procedures for comparing samples with multiple endpoints. Biometrics 40: 1079–1087PubMedCrossRefGoogle Scholar
  36. Peto R (1995) Clinical trials. In: Price P, Sikora K (eds) Treatment of Cancer. Chapman & Hall, London, pp 1039–1043Google Scholar
  37. Peto R, Peto J (1972) Asymptotically efficient rank invariant procedures. J Roy Stat Soc A 135: 185–207CrossRefGoogle Scholar
  38. Pocock SJ (1977) Group sequential methods in the design and analysis of clinical trials. Biometrics 64: 191–199CrossRefGoogle Scholar
  39. Pocock SJ (1983) Clinical trials. A practical approach. Wiley, ChichesterGoogle Scholar
  40. Queisser W, Hartung G, Kopp-Schneider A, Diezler P, Hagmüller E, Baur A, Weniger J, Wojatschek C, Janssen N, Hossfeld DK, Lindemann H, Schnabel T, Edler L (2000) Adjuvant radio-chemotherapy with 5-fluorouracil and leucovorin in stage II and III rectal cancer: 12 months vs. 6 months of therapy. Onkol 23 (4): 334–339CrossRefGoogle Scholar
  41. Rasch D, Herrendörfer G, Bock J, Victor N, Guiard V (Hrsg) (1996) Verfahrensbibliothek. Versuchsplanung und Auswertung, Bd I R. Oldenbourg, MünchenGoogle Scholar
  42. Rasch D, Herrendörfer G, Bock J, Victor N, Guiard V (Hrsg) (1998) Verfahrensbibliothek. Versuchsplanung und Auswertung, Bd II R. Oldenbourg, MünchenGoogle Scholar
  43. SAS Institute (1997) SAS/SAT Software: Changes and enhancements. Rel. 6. 12. SAS Inst., Cary/NCGoogle Scholar
  44. Schmoor C, Olschewski M, Schumacher M (1996) Randomized and non-randomized patients in clinical trials: Experiences with comprehensive cohort studies. Stat Med 15: 263–271PubMedCrossRefGoogle Scholar
  45. Schwartz D, Flamant R, Lellouch J (1980) Clinical trials. Academic Press, New YorkGoogle Scholar
  46. Senn S (1997) Statistical issues in drug development, Wiley, ChichesterGoogle Scholar
  47. Simon RM, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979–985PubMedCrossRefGoogle Scholar
  48. Solomon MJ, Laxamana A, Devore L, McLeod RS (1994) Randomized controlled clinical trials in surgery. Surgery 115: 707–712PubMedGoogle Scholar
  49. Spilker B (1984) Guide to clinical studies and developing protocols. Raven, New YorkGoogle Scholar
  50. Spriet A, Dupin-Spriet T (1997) Good practice of clinical drug trials, 2nd edn. Karger, BaselGoogle Scholar
  51. Taylor KM, Margolese RG, Soskoline CL (1984) Physician’s reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310: 1363–1367PubMedCrossRefGoogle Scholar
  52. Weber E (1982) Aspekte zum Aufbau und zur Durchführung randomisierter Therapiestudien. In: Bokelmann D, Schreiber HW (Hrsg) Ergebnisse der Chirurgischen Onkologie 3. Enke, Stuttgart, S 3–6Google Scholar
  53. WHO (1979) WHO Handbook for reporting results of cancer treatment. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • L. Edler

There are no affiliations available

Personalised recommendations